公开(公告)号：US20240335480A1

公开(公告)日：2024-10-10

申请号：US18579100

申请日：2022-07-14

申请人： Astellas Pharma Inc. ,  OSAKA UNIVERSITY ,  National Center for Child Health and Development

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/071

CPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/069 ,  C12N2506/02 ,  C12N2513/00

摘要： An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

公开(公告)号：US12090253B2

公开(公告)日：2024-09-17

申请号：US16728138

申请日：2019-12-27

申请人： VeriGraft AB

发明人： Suchitra Sumitran-Holgersson ,  Michael Olausson

IPC分类号： A61L27/50 ,  A61F2/06 ,  A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K35/34 ,  A61K35/44 ,  A61K35/545 ,  A61L27/24 ,  A61L27/36 ,  A61L27/38 ,  A61L27/54 ,  C12N5/071 ,  C12N5/078

CPC分类号： A61L27/507 ,  A61K35/14 ,  A61K35/28 ,  A61K35/34 ,  A61K35/44 ,  A61K35/545 ,  A61L27/24 ,  A61L27/3616 ,  A61L27/3625 ,  A61L27/3808 ,  A61L27/3826 ,  A61L27/3834 ,  A61L27/3886 ,  A61L27/54 ,  C12N5/0641 ,  C12N5/0691 ,  C12N5/0692 ,  A61F2/06 ,  A61F2/062 ,  A61F2240/001 ,  A61K2035/124 ,  A61L2300/252 ,  A61L2300/64 ,  A61L2430/34 ,  C12N2533/54 ,  C12N2533/90

摘要： The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.

公开(公告)号：US20240269148A1

公开(公告)日：2024-08-15

申请号：US18443160

申请日：2024-02-15

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas E. Ichim ,  Famela Ramos ,  James Veltmeyer ,  Timothy G. Dixon

IPC分类号： A61K31/567 ,  A61K35/44 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/567 ,  A61K35/44 ,  A61K45/06 ,  A61P35/00

摘要： Parallels between pregnancy and cancer have been historically made, however, the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and anti-angiogenic immunotherapy. In another embodiment, abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy. Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V therapy.

公开(公告)号：US20240158488A1

公开(公告)日：2024-05-16

申请号：US17918675

申请日：2021-04-15

申请人： Hackensack Meridian Health Center for Discovery and Innovation

发明人： Jason Mathew Butler ,  Pradeep Ramalingam

IPC分类号： C07K16/20 ,  A61K35/28 ,  A61K35/44 ,  A61P7/00 ,  C12N15/113

CPC分类号： C07K16/205 ,  A61K35/28 ,  A61K35/44 ,  A61P7/00 ,  C12N15/113 ,  C07K2317/76 ,  C12N2310/14

摘要： The described invention provides a method for rejuvenating an aging blood and vascular system comprising aging-associated hematopoietic defects in an aging hematopoietic microenvironment of bone marrow including deteriorating vascular integrity, reduced hematopoietic stem cell function, or both. The method includes administering to a subject a pharmaceutical composition comprising an inhibitor of a pro-aging angiocrine factor, a splice variant, or a fragment thereof, and a pharmaceutically acceptable carrier. The described invention has identified thrombospondin-1 as a candidate pro-aging factor.

公开(公告)号：US11912986B2

公开(公告)日：2024-02-27

申请号：US17028836

申请日：2020-09-22

申请人： The Regents of the University of California

发明人： Prashant Mali ,  Udit Parekh ,  Yan Wu ,  Kun Zhang

IPC分类号： C12N15/10 ,  C12N5/071 ,  C12N15/86 ,  A61K35/44

CPC分类号： C12N15/1065 ,  A61K35/44 ,  C12N5/069 ,  C12N15/86 ,  C12N2506/45 ,  C12N2740/15043 ,  C12N2740/15052

摘要： Understanding the complex effects of genetic perturbations on cellular state and fitness in human pluripotent stem cells (hPSCs) has been challenging using traditional pooled screening techniques which typically rely on unidimensional phenotypic readouts. Here, Applicants use barcoded open reading frame (ORF) overexpression libraries with a coupled single-cell RNA sequencing (scRNA-seq) and fitness screening approach, a technique we call SEUSS (ScalablE fUnctional Screening by Sequencing), to establish a comprehensive assaying platform. Using this system, Applicants perturbed hPSCs with a library of developmentally critical transcription factors (TFs), and assayed the impact of TF overexpression on fitness and transcriptomic cell state across multiple media conditions. Applicants further leveraged the versatility of the ORF library approach to systematically assay mutant gene libraries and also whole gene families. From the transcriptomic responses, Applicants built genetic co-perturbation networks to identify key altered gene modules. Strikingly, we found that KLF4 and SNAI2 have opposing effects on the pluripotency gene module, highlighting the power of this method to characterize the effects of genetic perturbations. From the fitness responses, Applicants identified ETV2 as a driver of reprogramming towards an endothelial-like state.

公开(公告)号：US20230414671A1

公开(公告)日：2023-12-28

申请号：US18464908

申请日：2023-09-11

申请人： ANGIOCRINE BIOSCIENCE, INC.

发明人： Michael Daniel Ginsberg ,  Daniel Joseph Nolan ,  Claude Geoffrey Davis ,  Paul William Finnegan

IPC分类号： A61K35/28 ,  C12N5/0789 ,  A61K35/44

CPC分类号： A61K35/28 ,  C12N2502/28 ,  A61K35/44 ,  C12N5/0647

摘要： The present disclosure relates to the field of hematopoietic stem or progenitor cell transplantation. More specifically, methods, compositions and kits for improving expansion and engraftment of hematopoietic stem or progenitor cells by co-culturing and co-administering with endothelial cells are provided. The methods, compositions and kits are useful for treating various disorders relating to deficiencies in hematopoiesis caused by disease or myeloablative treatments.

公开(公告)号：US20230287030A1

公开(公告)日：2023-09-14

申请号：US18118909

申请日：2023-03-08

申请人： The General Hospital Corporation

发明人： Harald C. Ott ,  Xi Ren ,  Jordan P. Bloom ,  Taufiek Konrad Rajab

IPC分类号： C07H13/04 ,  A61L27/38 ,  A61L27/54 ,  C12N5/07 ,  A61K31/655 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/407 ,  A61K35/42 ,  A61K35/44 ,  A61L27/36

CPC分类号： C07H13/04 ,  A61L27/3813 ,  A61L27/3826 ,  A61L27/383 ,  A61L27/3808 ,  A61L27/54 ,  C12N5/06 ,  A61K31/655 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/407 ,  A61K35/42 ,  A61K35/44 ,  A61L27/3633 ,  A61L2300/414 ,  A61L2300/256 ,  A61L2300/42 ,  A61L2300/406

摘要： The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.

公开(公告)号：US11738054B2

公开(公告)日：2023-08-29

申请号：US16631233

申请日：2018-07-20

申请人： ATOMIC ENERGY OF CANADA LIMITED/ÈNERGIE ATOMIQUE DU CANADA LIMTÈE

发明人： Dmitry Klokov ,  Soji Sebastian ,  Yevgeniya Le

IPC分类号： A61K35/545 ,  A61K35/34 ,  A61K35/44 ,  A61K41/00 ,  A61P21/00

CPC分类号： A61K35/545 ,  A61K35/34 ,  A61K35/44 ,  A61K41/0057 ,  A61P21/00

摘要： In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 preconditioned stem cells is obtained by exposing stem cells to LDR. Uses of the preconditioned stem cells are also provided. In other aspects, the stem cells are muscle stem cells.

公开(公告)号：US20230181648A1

公开(公告)日：2023-06-15

申请号：US17902482

申请日：2022-09-02

申请人： Indiana University Research and Technology Corp

发明人： Mervin C. Yoder ,  David P. Basile

IPC分类号： A61K35/44 ,  A61P9/10 ,  A61P13/12 ,  A61K45/06 ,  C12N5/071

CPC分类号： A61K35/44 ,  A61P9/10 ,  A61P13/12 ,  A61K45/06 ,  C12N5/069 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/45

摘要： The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.

公开(公告)号：US11674131B2

公开(公告)日：2023-06-13

申请号：US16700533

申请日：2019-12-02

申请人： Ross Ward ,  Jory Scott

发明人： Ross Ward ,  Jory Scott

IPC分类号： C12N13/00 ,  C12N5/071 ,  C12N5/0781 ,  C12N5/0783 ,  C12N5/0787 ,  C12N5/078 ,  C12N5/0786 ,  C12N5/0789 ,  A61K35/44

CPC分类号： C12N13/00 ,  A61K35/44 ,  C12N5/0691 ,  C12N5/0635 ,  C12N5/0637 ,  C12N5/0642 ,  C12N5/0644 ,  C12N5/0645 ,  C12N5/0647

摘要： The present invention is directed to indirect ultrasonic cavitation-derived perivascular cells, to methods of use of a perivascular cell composition, to a method of processing a tissue and to an apparatus for the processing of a tissue. The methods include the mechanic indirect ultrasonication of a cellular non-structural tissue, and produce a perivascular fraction which includes perivascular cells. The methods of use are directed to the treatment of a variety of diseases and disorders and to the improvement of a tissue in a subject. The apparatus is provided for the processing of cellular non-structural tissue.